Detailed answers about CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED, including incorporation, status, business activity, and accounts information.
When was CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED founded?
CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED was officially incorporated on 17 March 2025 and is registered under company number 16321718. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED?
CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED do?
CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED operates in the following sector: 86900 - Other human health activities. This provides insight into the company's primary business activity and industry focus.
What is CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED's registered address?
The registered office address of CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED is 19 THE GROVE, SUTTON COLDFIELD, ENGLAND, B74 3UB. This is the official address filed with Companies House for legal and statutory correspondence.
Is CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED financially stable?
Financial accounts for CLINICAL INDEPENDENT PRESCRIBING SOLUTIONS LIMITED are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.